Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ark Genomic Revolution ETF
(NY:
ARKG
)
28.23
-0.79 (-2.72%)
Official Closing Price
Updated: 8:00 PM EDT, Sep 21, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ark Genomic Revolution ETF
< Previous
1
2
3
4
5
6
Next >
Cathie Wood Is Selling Gene Editing Stocks. Here’s Why.
June 02, 2022
Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?
Via
InvestorPlace
Know The 2 Healthcare Companies Cathie Wood's Ark Invest Bought On Friday
April 02, 2022
Cathie Wood's Ark Invest may have had a disappointing 2021, but the fund's purchases/liquidations are always watched keenly by investors. On Friday, ETFs managed by...
Via
Benzinga
Tesla Bull Cathie Wood Bought $1M Shares In This Biotech Stock Today
March 24, 2022
Tesla Inc (NASDAQ: TSLA) bull Cathie Wood led Ark Investment Management on Thursday further raised its exposure in China-based biotech company Burning Rock Biotech Ltd (NASDAQ: BNR).
Via
Benzinga
4 Big Ark Innovation Components Report Earnings This Week: Could It Spell More Danger For Cathie Wood?
February 23, 2022
The Ark Funds ETFs have been hit hard in 2022 with growth stocks among the laggards as investors turned to value stocks. Many stockholders have begun to question ...
Via
Benzinga
Psyched: Cathie Wood Invests In Psychedelics Co ATAI, Bill Approved in Utah, AI Startup To 'Design States Of Mind'
February 14, 2022
The psychedelics sector received its latest sign of acceptance from Wall Street with famed investor Cathie Wood taking a position ...
Via
Benzinga
A Leaky ARKK
January 04, 2022
In a year when everything skyrocketed to nauseating highs, Cathie’s momentum-obsessed investing style was a dud.
Via
Talk Markets
Neck Cream Reversal
November 18, 2021
Cathie Wood's ARKG is down about 50% over the past 9 months.
Via
Talk Markets
Cathie Wood Is Buying this Peter Thiel-Backed Psychedelics Stock For Ark Funds
February 09, 2022
There’s a new psychedelics company being added to an ETF from Cathie Wood. What Happened: The Ark Genomic Revolution ETF (BATS: ARKG) took an initial position in shares of...
Via
Benzinga
Cathie Wood's Ark Invest Sheds Stake In This Large-Cap Pharma Ahead Of Earnings
February 05, 2022
Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed.
Via
Benzinga
Ark Funds Launching New Fund That Could Invest In Private Companies
February 04, 2022
One of the biggest and most well-known ETF companies is launching a new closed-end fund that provides major differences from its existing ETFs.
Via
Talk Markets
Ark Funds Launching New Fund That Could Invest In Private Companies
February 04, 2022
One of the biggest and most well-known ETF companies is launching a new closed-end fund that provides major differences from its existing ETFs....
Via
Benzinga
Small Cap Biotech Stocks: Is it time to start trading?
January 31, 2022
It’s time to trade beaten-up small cap biotech stocks.
Via
Talk Markets
Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?
January 14, 2022
One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t...
Via
Benzinga
UiPath Stock Is Worth Believing in Here as Wood Holds Fast
December 30, 2021
Cathie Woods ARK Investment ETFs have loaded up on shares of UiPath despite the decline. PATH stock has plenty of upside from here.
Via
InvestorPlace
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
December 22, 2021
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022.
Via
Talk Markets
Cathie Wood Added To Stake In This Medical Technology Company As Its Shares Surged 6% On Friday
December 20, 2021
Cathie Wood’s Ark Investment Management on Friday bought 26,126 shares — estimated to be worth $163,026 — in Quantum-Si Inc (NASDAQ: QSI). Shares of the medical...
Via
Benzinga
Biotech Playbook 2021: No Help From Small Caps In Q4
December 14, 2021
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but...
Via
Talk Markets
Bionano Genomics Proves Not Everything Genetic is Gold
December 01, 2021
Bionano sells a $150,000 machine called Saphyr that does genetic mapping. It's a solid device, but its future remains in the future, as do BNGO stock fortunes.
Via
InvestorPlace
Cathie Wood Testing 'ARK On Steroids' As ARK Funds Struggle
November 24, 2021
Wood said ARK is testing a strategy to short stocks in the big benchmark indexes,
Via
Investor's Business Daily
Topics
Electric Vehicles
Exposures
Electric Vehicles
Don't Look Now, But Cathie Wood's Ark Is Taking On Water
November 24, 2021
Among the biggest losers over the last 48 hour tech stock volatility has been...well, everything in Cathie Wood's
Via
Talk Markets
Biotech Stocks are Due for a Rally
November 22, 2021
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums.
Via
Talk Markets
Yes, Cathie Wood's $700,000 Bitcoin Price Prediction Is Legit
November 21, 2021
A Bitcoin price prediction of $700,000 - more than 10 times the recent price - would strike most people as delusional. But this eye-popping target doesn't come from a Bitcoin fan. It comes from Wall...
Via
Talk Markets
Tesla (TSLA) Not Enough To Lift ARK Innovation (ARKK)
October 27, 2021
An updated look at Cathie Wood’s ARK ETFs relative strength versus the S&P 500 SPY ETF.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
ETF Battles: Finding the Top Genomics Biotech ETF – A Triple Header of ARKG vs IDNA vs GNOM
October 21, 2021
The search for therapies tackling chronic illnesses like cancer, diabetes, and heart disease has put stocks in the biotechnology and genomics industry sector on center stage.
Via
Talk Markets
Ginkgo Bioworks Stock Drops 20% After Short Sellers Call Company A 'Colossal Scam'
October 06, 2021
Shares of synthetic biology company Ginkgo Bioworks Holdings Inc (NYSE:
Via
Benzinga
Mike Khouw Sees Unusual Options Activity In ARK Genomic Revolution ETF
September 29, 2021
On CNBC's "Options Action," Mike Khouw said ARK Genomic Revolution ETF (BATS: ARKG) was active on Tuesday as it traded six times its average daily put volume....
Via
Benzinga
Biotech Playbook Revisited As Technicals Weaken
September 27, 2021
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still...
Via
Talk Markets
Look For The Q4 Biotech Bounce In Mid-Small Caps
September 17, 2021
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best...
Via
Talk Markets
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
September 09, 2021
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day.
Via
Talk Markets
3 Healthcare Stocks Cathie Wood Loves Right Now
September 03, 2021
Here's why the founder and CEO of ARK Invest set her sights on these three healthcare stocks.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.